Claims for Patent: 10,668,040

Summary for Patent: 10,668,040

Title:	Treatment of urea cycle disorders in neonates and infants
Abstract:	Nitrogen scavenging drugs such as glycerol phenylbutyrate can be administered safely to infants and toddlers with urea cycle disorders by adjusting the dosage based on one or more biomarkers selected from the group consisting of urinary-PAGN and plasma PAA:PAGN ratio.
Inventor(s):	Scharschmidt; Bruce (San Francisco, CA), Mokhtarani; Masoud (Walnut Creek, CA)
Assignee:	Horizon Therapeutics, LLC (Lake Forest, IL)
Application Number:	16/128,140
Patent Claims:	1. A method of treating a urea cycle disorder (UCD) in a patient under 2 years of age comprising administering glycerol phenylbutyrate to said patient at an initial daily dose which is administered at an initial frequency of administration; and if after said administration, said patient exhibits neurological symptoms, normal ammonia levels, and a ratio of plasma PAA to plasma PAGN of >2.5 or a level of plasma PAA of >500 .mu.g/mL, then administering said glycerol phenylbutyrate to said patient at a reduced daily dose while maintaining said initial frequency of administration, wherein the initial frequency of administration is 3 to 6 times daily, and wherein if said patient is in a hyperammonemic crisis, then said initial daily dose is 11.2 mL/m.sup.2/day, if said patient is not in a hyperammonemic crisis, then said initial daily dose is 8.5 mL/m.sup.2/day, and if said patient previously had been administered NaPBA or NaBz, then said initial daily dose is equal to 0.81 times the total number of grams of NaPBA powder the patient was receiving, or 0.86 times the total number of grams of in NaPBA tablet form the patient was receiving, or 0.5 times the total number of grams of in NaBz the patient was receiving. 2. A method of treating a urea cycle disorder (UCD) in a patient under 2 years of age comprising administering glycerol phenylbutyrate to said patient at an initial daily dose which is administered at an initial frequency of administration; and if after said administration said patient exhibits neurological symptoms, normal ammonia levels, and a ratio of plasma PAA to plasma PAGN of >2.5 or a level of plasma PAA of >500 .mu.g/mL, then administering said glycerol phenylbutyrate to said patient at a lower dose or increased frequency of administration while maintaining said daily dose, wherein the initial frequency of administration is 3 to 6 times daily, and wherein if said patient is in a hyperammonemic crisis, then said initial daily dose is 11.2 mL/m.sup.2/day, if said patient is not in a hyperammonemic crisis, then said initial daily dose is 8.5 mL/m.sup.2/day, and if said patient previously had been administered NaPBA or NaBz, then said initial daily dose is equal to 0.81 times the total number of grams of NaPBA powder the patient was receiving, or 0.86 times the total number of grams of in NaPBA tablet form the patient was receiving, or 0.5 times the total number of grams of in NaBz the patient was receiving. 3. A method of treating a urea cycle disorder (UCD) in a patient under 2 years of age comprising administering glycerol phenylbutyrate to said patient at an initial daily dose which is administered at an initial frequency of administration; and if after said administration said patient exhibits neurological symptoms, normal ammonia levels, and a ratio of plasma PAA to plasma PAGN of <2.5, then said glycerol phenylbutyrate to said patient should continue to be administered at the same dose and frequency and the patient evaluated for other causes of his or her neurological symptoms, wherein the initial frequency of administration is 3 to 6 times daily, and wherein if said patient is in a hyperammonemic crisis, then said initial daily dose is 11.2 mL/m.sup.2/day, if said patient is not in a hyperammonemic crisis, then said initial daily dose is 8.5 mL/m.sup.2/day, and if said patient previously had been administered NaPBA or NaBz, then said initial daily dose is equal to 0.81 times the total number of grams of NaPBA powder the patient was receiving, or 0.86 times the total number of grams of in NaPBA tablet form the patient was receiving, or 0.5 times the total number of grams of in NaBz the patient was receiving. 4. The method of claim 1, wherein said patient is less than about one month of age. 5. The method of claim 1, wherein said patient is from 1 month to two years of age. 6. The method of claim 1, wherein said neurological symptoms include headache, confusion, vomiting, lethargy, or any combination thereof. 7. The method of claim 2, wherein said patient is less than about one month of age. 8. The method of claim 2, wherein said patient is from 1 month to two years of age. 9. The method of claim 2, wherein said neurological symptoms include headache, confusion, vomiting, lethargy, or any combination thereof. 10. The method of claim 3, wherein said patient is less than about one month of age. 11. The method of claim 3, wherein said patient is from 1 month to two years of age. 12. The method of claim 3, wherein said neurological symptoms include headache, confusion, vomiting, lethargy, or any combination thereof.